Cryptosporidium infections are large contributors of child death and illness in heavily affected areas, yet low importance has been placed on both identifying the species and finding more treatment options outside of nitazoxanide for children and AIDS patients.

[4] As a result, C. hominis is most easily differentiated from C. parvum through genetic analysis via time-intensive PCR-restriction fragment length polymorphism or gene sequencing.

[5] The life cycle of Cryptosporidium hominis is similar to that of others of the genus with infective sporozoites from ingested oocysts invading gut epithelium.

The effectiveness of nitazoxanide in immunocompromised patients, however, is uncertain and current treatments revolve around boosting the host immune system to aid in symptom resolution.

[6] Current avenues for treatment include scanning the Cryptosporidium hominis genome for possible targets for vaccine development.